Perhaps no topic other than stage IIIA-N2 non-small-cell lung cancer management is as controversial among surgeons, radiologists and medical oncologists. Much of the debate relates to the choice between surgical resection and radiation as the local controlmodality. Although limited, available evidence from randomized controlled trails raised concerns about the role of surgical resection. However, there is no perfect study, and the results should not be over-interpreted. This mini review will scrutinize these trials, focusing on the study design, results and, most importantly, limitations, and will explore the possible role of surgery for stage IIIA-N2 non-small-cell lung cancer.OncologyRespiratory SystemSCI(E)1REVIEW390-94
International audienceBackground: Stage IIIA/B-N2 is a very heterogeneous group of patients and acco...
ObjectiveOptimal management of stage IIIA-N2 non–small cell lung cancer remains controversial. The s...
International audienceThis paper focuses on stage I, II and IIIA non-small cell lung cancer treatabl...
Locally advanced, stage IIIA-N2 Non-small cell lung cancer (NSCLC) represents a heterogeneous patien...
Abstract: Purpose of review Locally advanced non-small cell lung cancer (NSCLC) represents a therape...
【Abstract 】 The role of surgery in stage A-N2 non-small cell lung cancer (NSCLC) remains controversi...
According to the eighth edition of the tumor–node–metastasis classification, stage III non-small cel...
Standard treatment for resectable IIIa/N2 non-small-cell lung cancer (NSCLC) is still under debate. ...
Background: Surgery has been considered the most effective and standard treatment modality in non-sm...
About 40 % of patients with non-small-cell lung cancer (NSCLC) present with stage IV disease, while ...
Background: Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associat...
Surgical treatment of stage IIIA non-small cell lung cancer (NSCLC) remains a controversial area in ...
Abstract: Purpose of review Controversy exists regarding the optimal treatment of patients with stag...
OBJECTIVE: The surgical treatment of residual N2 disease following induction radio-chemotherapy (IT...
AbstractSurgical resection remains the standard of care for functionally operable early-stage non-sm...
International audienceBackground: Stage IIIA/B-N2 is a very heterogeneous group of patients and acco...
ObjectiveOptimal management of stage IIIA-N2 non–small cell lung cancer remains controversial. The s...
International audienceThis paper focuses on stage I, II and IIIA non-small cell lung cancer treatabl...
Locally advanced, stage IIIA-N2 Non-small cell lung cancer (NSCLC) represents a heterogeneous patien...
Abstract: Purpose of review Locally advanced non-small cell lung cancer (NSCLC) represents a therape...
【Abstract 】 The role of surgery in stage A-N2 non-small cell lung cancer (NSCLC) remains controversi...
According to the eighth edition of the tumor–node–metastasis classification, stage III non-small cel...
Standard treatment for resectable IIIa/N2 non-small-cell lung cancer (NSCLC) is still under debate. ...
Background: Surgery has been considered the most effective and standard treatment modality in non-sm...
About 40 % of patients with non-small-cell lung cancer (NSCLC) present with stage IV disease, while ...
Background: Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associat...
Surgical treatment of stage IIIA non-small cell lung cancer (NSCLC) remains a controversial area in ...
Abstract: Purpose of review Controversy exists regarding the optimal treatment of patients with stag...
OBJECTIVE: The surgical treatment of residual N2 disease following induction radio-chemotherapy (IT...
AbstractSurgical resection remains the standard of care for functionally operable early-stage non-sm...
International audienceBackground: Stage IIIA/B-N2 is a very heterogeneous group of patients and acco...
ObjectiveOptimal management of stage IIIA-N2 non–small cell lung cancer remains controversial. The s...
International audienceThis paper focuses on stage I, II and IIIA non-small cell lung cancer treatabl...